Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 005.05 INR -1.52% Market Closed
Market Cap: 914B INR
Have any thoughts about
Lupin Ltd?
Write Note

Lupin Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lupin Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Lupin Ltd
NSE:LUPIN
Interest Income Expense
-â‚ą3.3B
CAGR 3-Years
-59%
CAGR 5-Years
-1%
CAGR 10-Years
-30%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Interest Income Expense
-â‚ą1.8B
CAGR 3-Years
-70%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Interest Income Expense
-â‚ą810.4m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
5%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Interest Income Expense
â‚ą92m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Interest Income Expense
-â‚ą3B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
-10%
M
Mankind Pharma Ltd
NSE:MANKIND
Interest Income Expense
â‚ą1.4B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lupin Ltd
Glance View

Market Cap
913.7B INR
Industry
Pharmaceuticals

Lupin Ltd. is a global pharmaceutical powerhouse rooted in Mumbai, India, renowned for its commitment to providing high-quality, affordable medicines across a spectrum of therapeutic areas. Founded in 1968, this rapidly growing company has carved a niche in generics, specialty pharmaceuticals, and biotechnology. With a robust portfolio that includes over 1,500 products across various disciplines, particularly in cardiovascular, CNS, and anti-infective medications, Lupin has established itself as a key player in the global healthcare ecosystem. The company's strategic focus on research and development ensures a steady pipeline of innovative solutions tailored to meet the needs of patients and healthcare providers alike, positioning Lupin as a dynamic leader in the pharmaceutical industry. Driven by a global vision, Lupin operates in over 100 countries and has earned a reputation for excellence through its extensive manufacturing capabilities and adherence to stringent quality standards. The firm’s dedication to expanding its presence in developed markets, particularly in the U.S. and Europe, underscores its ambition to enhance healthcare access worldwide. For investors, Lupin represents an opportunity characterized by solid growth potential, as it continuously invests in R&D, strengthens its market position, and adapts to the evolving landscape of global healthcare. With a commitment to sustainability and a focus on creating value for stakeholders, Lupin Ltd. not only aims to thrive financially but also to enrich the lives of millions through its innovative healthcare solutions.

LUPIN Intrinsic Value
1 435.1 INR
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Lupin Ltd's Interest Income Expense?
Interest Income Expense
-3.3B INR

Based on the financial report for Jun 30, 2024, Lupin Ltd's Interest Income Expense amounts to -3.3B INR.

What is Lupin Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-30%

Over the last year, the Interest Income Expense growth was -8%. The average annual Interest Income Expense growth rates for Lupin Ltd have been -59% over the past three years , -1% over the past five years , and -30% over the past ten years .

Back to Top